



Notice of the Difference from Financial Results Forecasts for the fiscal year ended March 31, 2017

Tokyo, Japan –12 May, 2017: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) today announces to confirm the differences between its financial results forecast revised on February 10, 2017, for the fiscal year ended March 31, 2017 (from April 1, 2016 to March 31, 2017) and the actual results announced today.

1. Change from Forecast for fiscal year ended March 31, 2017 (from April 1, 2016 to March 31, 2017)

(1) Consolidated operation results

	Revenue	Operating income	Net income before taxes	Net income attributable to owners of the parent company	Net basic earnings per share
	Million yen	Million yen	Million yen	Million yen	Yen
Previous forecast (A)	19,426	12,431	N.A.	N.A.	N.A.
Actual results (B)	18,901	12,389	12,483	9,797	579.97
Difference (B-A)	(525)	(42)	-	-	-
Rate of Change (%)	(2.7)	(0.3)	-	-	-
Previous year ended March 2016 (reference)	8,151	1,075	(3,297)	(1,432)	(93.60)

(2) Reason for the difference

As we announced in ‘Notice Concerning Forecast Revision for the FY2016’ on February 10, 2017, all our partnered programs continue to advance. However, clinical programme timelines based on the development strategies and schedules of the partners remain subject to phasing variations and may differ from our expectation, which has resulted in the differences as reported above.

-Ends-

Enquiries:

Sosei Group Corporation
Harumi BANSE,
Investor Relations
+81-(0)3-5210-3399
hbanse@sosei.com

About Sosei

Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of

Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing its GPCR structure-based drug design platform technology, Sosei has established a product pipeline with first/best in class potential. Through development and commercialization partnerships, Sosei has already delivered two bronchodilators for COPD, which generate significant and stable revenue streams that enable further growth. Sosei partners include Novartis, Allergan, AstraZeneca, Daiichi Sankyo, MorphoSys, Teva and Pfizer and we are actively looking for new partnerships to enhance the development of our products and help us deliver them to patients worldwide.

For further information about Sosei, please visit www.osei.com/en.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.